Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

22-Jul-2015 - Biotie announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related end-of-dose "wearing-off".The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo ...

Biotie: BTT1023 receives positive opinion for Orphan Drug Designation

19-Feb-2015 - The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic ...

Biotie: Tozadenantmeets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease

14-Dec-2012 - Biotie reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' ...

Biotie: Topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease

24-May-2011 - Biotie Therapies Corp. announced results from an exploratory phase 2a study of its HPPD inhibitor SYN118 in Parkinson's disease (PD). These data do not show a significant improvement in measures of PD motor function when compared to placebo. Biotie will consider development options for the ...

Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

11-Apr-2011 - Biotie Therapies Corp. announced the start of a Phase 2b trial evaluating SYN115 in Parkinson's Disease (PD). Results from the study are expected in the first half of 2013.SYN115 is an orally bioavailable potent and selective adenosine A2a receptor antagonist. Adenosine A2a inhibition has been ...

Biotie Announces Positive Results from First Two Phase III Studies with Nalmefene in Alcohol Dependence

04-Jan-2011 - Biotie's partner, H. Lundbeck A/S, has announced that it has completed two Phase III clinical trials evaluating nalmefene for the treatment of alcohol dependence (ESENSE1, SENSE). Lundbeck expects to complete a further efficacy study (ESENSE2) in 2Q 2011 and plans to file a marketing ...

Biotie regains rights to develop PDE10 inhibitors for CNS disorders

19-Oct-2010 - Biotie announced that it will regain rights to compounds relating to PDE10 inhibition for the treatment of CNS disorders, including schizophrenia. The compounds were the subject of a four-year collaboration with Wyeth (which was acquired by Pfizer in 2009) which started in 2006 and which yielded ...

Biotie completes Phase I with VAP-1 antibody - BTT-1023 continues to demonstrate favourable safety profile

15-Sep-2010 - Biotie reported top-line data from a recently completed Phase I study with its fully human VAP-1 monoclonal antibody (BTT-1023) in patients with plaque psoriasis. The study evaluated the safety, tolerability, and pharmacokinetics of repeated doses of intravenously administered antibody in 26 ...

Biotie reports positive top-line data from clinical study with its third generation oral PDE4 inhibitor

ELB353 is well tolerated and shows clear pharmacological activity

28-Apr-2010 - Biotie reported that it has successfully completed a Phase I trial with its orally administered phosphodiesterase 4 (PDE4) inhibitor ELB353, intended for the treatment of chronic obstructive pulmonary disease (COPD). The study evaluated the safety, tolerability, pharmacokinetic characteristics ...

Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease

23-Apr-2010 - Biotie announced that it maintains global development and commercialization rights to BTT-1023 (ex-Japan, Taiwan, Singapore, New Zealand, and Australia), following Roche's decision not to exercise its opt-in right for strategic portfolio reasons. BTT-1023 is Biotie's novel fully human monoclonal ...